Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial

To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively ti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2013-06, Vol.65 (6), p.1430
Hauptverfasser: Navarro-Millán, Iris, Charles-Schoeman, Christina, Yang, Shuo, Bathon, Joan M, Bridges, Jr, S Louis, Chen, Lang, Cofield, Stacey S, Dell'Italia, Louis J, Moreland, Larry W, O'Dell, James R, Paulus, Harold E, Curtis, Jeffrey R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page 1430
container_title Arthritis & rheumatology (Hoboken, N.J.)
container_volume 65
creator Navarro-Millán, Iris
Charles-Schoeman, Christina
Yang, Shuo
Bathon, Joan M
Bridges, Jr, S Louis
Chen, Lang
Cofield, Stacey S
Dell'Italia, Louis J
Moreland, Larry W
O'Dell, James R
Paulus, Harold E
Curtis, Jeffrey R
description To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.
doi_str_mv 10.1002/art.37916
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1356997567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2984246941</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-d7a20aadbff4b1deae05e72a2bba7291eb5d4d9c6e40d675b5b56d5b34ed86c53</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozvhY-Ack4LqaR5NadzL4AsGNroebya3N0DY1SdH5Sf5LMzhu5S4uXL5z7uEQcsbZJWdMXEFIl7Kqud4jc65EXTAu-T6ZCyl0oXjNZ-QoxjXLrFTykMyELDVjVTkn34sWhneM1A20c6Mfg0_ohkghRr9ykNDST5da2mNqfQr4lU_UB7ryvXEDJOcHmloMMG62Hgih29DQ4tRD8s7SnK0NLrl4QwPGqUuRNsH3Ww3NdpB6HBL1zT_KzDnoTshBA13E090-Jm_3d6-Lx-L55eFpcftcjELWqbAVCAZgTdOUhlsEZAorAcIYqETN0Shb2nqlsWRWV8rk0VYZWaK91islj8nFr2-u4mPCmJZrP4Uhv1xyqXRdV0pXmTrfUZPp0S7H4HoIm-Vfs_IH8OGAeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356997567</pqid></control><display><type>article</type><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</creator><creatorcontrib>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</creatorcontrib><description>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P &lt; 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 1529-0131</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.37916</identifier><identifier>PMID: 23460074</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject><![CDATA[Adult ; Aged ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Cholesterol ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Drug therapy ; Drug Therapy, Combination ; Etanercept ; Female ; Humans ; Hydroxychloroquine - administration & dosage ; Hydroxychloroquine - therapeutic use ; Immunoglobulin G - administration & dosage ; Immunoglobulin G - therapeutic use ; Male ; Methotrexate ; Methotrexate - administration & dosage ; Methotrexate - therapeutic use ; Middle Aged ; Receptors, Tumor Necrosis Factor - administration & dosage ; Receptors, Tumor Necrosis Factor - therapeutic use ; Sulfasalazine - administration & dosage ; Sulfasalazine - therapeutic use ; Treatment Outcome]]></subject><ispartof>Arthritis &amp; rheumatology (Hoboken, N.J.), 2013-06, Vol.65 (6), p.1430</ispartof><rights>Copyright © 2013 by the American College of Rheumatology.</rights><rights>Copyright © 2013 by the American College of Rheumatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23460074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navarro-Millán, Iris</creatorcontrib><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Yang, Shuo</creatorcontrib><creatorcontrib>Bathon, Joan M</creatorcontrib><creatorcontrib>Bridges, Jr, S Louis</creatorcontrib><creatorcontrib>Chen, Lang</creatorcontrib><creatorcontrib>Cofield, Stacey S</creatorcontrib><creatorcontrib>Dell'Italia, Louis J</creatorcontrib><creatorcontrib>Moreland, Larry W</creatorcontrib><creatorcontrib>O'Dell, James R</creatorcontrib><creatorcontrib>Paulus, Harold E</creatorcontrib><creatorcontrib>Curtis, Jeffrey R</creatorcontrib><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><title>Arthritis &amp; rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheum</addtitle><description>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P &lt; 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - administration &amp; dosage</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Cholesterol</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxychloroquine - administration &amp; dosage</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Immunoglobulin G - administration &amp; dosage</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Male</subject><subject>Methotrexate</subject><subject>Methotrexate - administration &amp; dosage</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Receptors, Tumor Necrosis Factor - administration &amp; dosage</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Sulfasalazine - administration &amp; dosage</subject><subject>Sulfasalazine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>2326-5191</issn><issn>1529-0131</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMozvhY-Ack4LqaR5NadzL4AsGNroebya3N0DY1SdH5Sf5LMzhu5S4uXL5z7uEQcsbZJWdMXEFIl7Kqud4jc65EXTAu-T6ZCyl0oXjNZ-QoxjXLrFTykMyELDVjVTkn34sWhneM1A20c6Mfg0_ohkghRr9ykNDST5da2mNqfQr4lU_UB7ryvXEDJOcHmloMMG62Hgih29DQ4tRD8s7SnK0NLrl4QwPGqUuRNsH3Ww3NdpB6HBL1zT_KzDnoTshBA13E090-Jm_3d6-Lx-L55eFpcftcjELWqbAVCAZgTdOUhlsEZAorAcIYqETN0Shb2nqlsWRWV8rk0VYZWaK91islj8nFr2-u4mPCmJZrP4Uhv1xyqXRdV0pXmTrfUZPp0S7H4HoIm-Vfs_IH8OGAeg</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Navarro-Millán, Iris</creator><creator>Charles-Schoeman, Christina</creator><creator>Yang, Shuo</creator><creator>Bathon, Joan M</creator><creator>Bridges, Jr, S Louis</creator><creator>Chen, Lang</creator><creator>Cofield, Stacey S</creator><creator>Dell'Italia, Louis J</creator><creator>Moreland, Larry W</creator><creator>O'Dell, James R</creator><creator>Paulus, Harold E</creator><creator>Curtis, Jeffrey R</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20130601</creationdate><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><author>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-d7a20aadbff4b1deae05e72a2bba7291eb5d4d9c6e40d675b5b56d5b34ed86c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - administration &amp; dosage</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Cholesterol</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxychloroquine - administration &amp; dosage</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Immunoglobulin G - administration &amp; dosage</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Male</topic><topic>Methotrexate</topic><topic>Methotrexate - administration &amp; dosage</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Receptors, Tumor Necrosis Factor - administration &amp; dosage</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Sulfasalazine - administration &amp; dosage</topic><topic>Sulfasalazine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navarro-Millán, Iris</creatorcontrib><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Yang, Shuo</creatorcontrib><creatorcontrib>Bathon, Joan M</creatorcontrib><creatorcontrib>Bridges, Jr, S Louis</creatorcontrib><creatorcontrib>Chen, Lang</creatorcontrib><creatorcontrib>Cofield, Stacey S</creatorcontrib><creatorcontrib>Dell'Italia, Louis J</creatorcontrib><creatorcontrib>Moreland, Larry W</creatorcontrib><creatorcontrib>O'Dell, James R</creatorcontrib><creatorcontrib>Paulus, Harold E</creatorcontrib><creatorcontrib>Curtis, Jeffrey R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navarro-Millán, Iris</au><au>Charles-Schoeman, Christina</au><au>Yang, Shuo</au><au>Bathon, Joan M</au><au>Bridges, Jr, S Louis</au><au>Chen, Lang</au><au>Cofield, Stacey S</au><au>Dell'Italia, Louis J</au><au>Moreland, Larry W</au><au>O'Dell, James R</au><au>Paulus, Harold E</au><au>Curtis, Jeffrey R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</atitle><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheum</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>65</volume><issue>6</issue><spage>1430</spage><pages>1430-</pages><issn>2326-5191</issn><eissn>1529-0131</eissn><eissn>2326-5205</eissn><coden>ARHEAW</coden><abstract>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P &lt; 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23460074</pmid><doi>10.1002/art.37916</doi></addata></record>
fulltext fulltext
identifier ISSN: 2326-5191
ispartof Arthritis & rheumatology (Hoboken, N.J.), 2013-06, Vol.65 (6), p.1430
issn 2326-5191
1529-0131
2326-5205
language eng
recordid cdi_proquest_journals_1356997567
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Aged
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Cholesterol
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Drug therapy
Drug Therapy, Combination
Etanercept
Female
Humans
Hydroxychloroquine - administration & dosage
Hydroxychloroquine - therapeutic use
Immunoglobulin G - administration & dosage
Immunoglobulin G - therapeutic use
Male
Methotrexate
Methotrexate - administration & dosage
Methotrexate - therapeutic use
Middle Aged
Receptors, Tumor Necrosis Factor - administration & dosage
Receptors, Tumor Necrosis Factor - therapeutic use
Sulfasalazine - administration & dosage
Sulfasalazine - therapeutic use
Treatment Outcome
title Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A57%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20lipoproteins%20associated%20with%20methotrexate%20or%20combination%20therapy%20in%20early%20rheumatoid%20arthritis:%20results%20from%20the%20treatment%20of%20early%20rheumatoid%20arthritis%20trial&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Navarro-Mill%C3%A1n,%20Iris&rft.date=2013-06-01&rft.volume=65&rft.issue=6&rft.spage=1430&rft.pages=1430-&rft.issn=2326-5191&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/art.37916&rft_dat=%3Cproquest_pubme%3E2984246941%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356997567&rft_id=info:pmid/23460074&rfr_iscdi=true